Facile synthesis of two azete-steroid derivatives and theoretical evaluation of its interaction with the aromatase enzyme

Year 2019, Volume: 47 Issue: 4, 415 - 428, 01.12.2019

Figueroa Lauro , Diaz Francisco Rosas Nexticapa Garcimarrero Alejandra Mateu Virginia Hernandez Patricia Pool Eduardo Lopez Ramos Hau Lenin Borges Yaritza

https://doi.org/10.15671/hjbc.602183

Abstract

Several aromatase inhibitors
have used for the treatment of breast cancer; however, some of these drugs may
produce some side effects such as endometrial cancer and bone loss. The aim of
this study was to synthesize two new azete-steroid derivatives (compounds 9
or 10) to evaluate its theoretical interaction with an aromatase enzyme
(2wd3) using anastrozole and exemestane as controls in a docking model. The
preparation of 9 and 10 was carried out using a series of
reactions which involves amination, etherification, nitration, and addition.
Chemical structure of the compounds was confirmed using elemental analysis and
NMR spectrum. The results showed that compounds 9 or 10 could
bind to a different type of aminoacid residues involved in of 2wd3 protein
surface compared anastrozole and exemestane; this phenomenon may exert changes
in the biological activity of aromatase enzyme. All data suggest that compounds
9 or 10 could be an alternative for the treatment of breast
cancer.

Keywords

Azete, steroid, derivative

Supporting Institution

University Autonomous of Campeche

References

• 1. M.D. Pegram, G.E. Konecny. C. O'Callaghan, M. Beryt. R. Pietras. D.J. Slamon, Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer, J Natl Cancer Inst., 96 (2004) 739-7492. K.C. Chu, C.A. Lamar, H.P. Freeman, Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment, Cancer., 97 (2003) 2853-28603. B.N. Polite, O.I. Olopade, Breast cancer and race: a rising tide does not lift all boats equally, Perspect Biol Med., 48 (2005), 166-1754. R.T. Chlebowski, Z. Chen, G.L. Anderson, T. Rohan, A. Aragaki, D. Lane, L.L. Adams, Ethnicity and breast cancer: factors influencing differences in incidence and outcome, J Natl Cancer Inst., 97 (2005) 439-4485. L.J. Pierce, L.F. Hutchins, S.R. Green, D.L. Lew, J.R. Gralow, R.B. Livingston, K.S. Albain, equencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer, J Clin Oncol., 23 (2005) 24-296. B. Gerber, A. Krause, T. Reimer, I. Mylonas, J. Makovitzky, W. Janni, Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology, Clin Cancer Res., 12 (2006) 1245-12507. M. Colleoni, W. Luo, P. Karlsson, J. Chirgwin, S. Aebi, G. Jerusalem, C. Kamby, Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol., 19 (2018) 127-1388. S. De Placido, C. Gallo, M. De Laurentiis, G. Bisagni, G. Arpino, M.G. Sarobba, F. Cognetti, Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, Lancet Oncol., 19 (2018) 474-4859. P. Brožič, P. Kocbek, M. Sova, J. Kristl, S. Martens, J. Adamski, T.L. Rižner, Flavonoids and cinnamic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1, Mol Cell Endocrinol., 301 (2009) 229-23410. M. Salah, A.S. Abdelsamie, M. Frotscher, Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges, Mol Cell Endocrinol., 18 (2018) 0303-720711. G. Yang, S. Nowsheen, K. Aziz, A.G. Georgakilas, Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs, Pharmacol Therapeut., 139 (2013) 392-40412. J.E. Lester, D. Dodwell, O.P. Purohit, S.A. Gutcher, S.P. Ellis, R. Thorpe, R.E. Coleman, Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer, Clin Cancer Res., 14 (2008) 6336-634213. M.C. Yang, C. Peng, H. Huang, L. Yang, X.H. He, W. Huang, H. Cui, B. Han, Organocatalytic Asymmetric Synthesis of Spiro-oxindole Piperidine Derivatives That Reduce Cancer Cell Proliferation by Inhibiting MDM2–p53 Interaction, Org Lett., 19 (2017) 6752-6755 14. B. Su, S. Landini, D.D. Davis, R.W. Brueggemeier, Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells, J Med Chem., 50 (2007) 1635-1644
• 15. C. Ding, Y. Zhang, H. Chen, Z. Yang, C. Wild, N. Ye, C. Ester, A. Xiong, M. White, Q. Sheng, J. Zhou, Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis, J. Med. Chem., 56 (2013) 1-3116. T. Akama, Y. Shida, T. Sugaya, H. Ishida, K. Gomi, M. Kasai, Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer, J. Med. Chem., 39 (1996) 3461-346917. P. Dandawate, E. Khan, S. Padhye, H. Gaba, S. Sinha, J. Deshpande, S. Venkateswara, M. Khetmalas, A. Ahmad, F. Sarkar, Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells, Bioorg. Med. Chem. Lett., 22 (2012) 3104-310818. G. Macindoe, L. Mavridis, V. Venkatraman, M. Devignes, D. Ritchie, HexServer: an FFT-based protein docking server powered by graphics processors, Nucleic acids Res., 38 (2010) W445-W449.19. Stander, F. Joubert, A. Joubert, Docking, synthesis, and in vitro evaluation of antimitotic estrone analogs, Chem Biol Drug Des., 77 (2011) 173-181.20. N. Nishimura, K. Kobayashi, Self‐Assembly of a Cavitand‐Based Capsule by Dynamic Boronic Ester Formation, Ang. Chem. Int. Ed., 47 (2008) 6255-6258.21. V. Temml, T. Kaserer, Z. Kutil, P. Landa, T. Vanek, D. Schuster, Pharmacophore modeling for COX-1 and-2 inhibitors with LigandScout in comparison to Discovery Studio, Future Med Chem., 6 (2014) 1869-1881.22. L. Woo, T. Jackson, A. Putey, G. Cozier, P. Leonard, K. Acharya, B. Potter, Highly potent first examples of dual aromatase− steroid sulfatase inhibitors based on a biphenyl template, J. Med. Chem., 53 (2010) 2155-2170.23. E. Hazai, S. Kovács, L. Demkó, Z. Bikádi, DockingServer: molecular docking calculations online, Acta Pharm Hung., 79 (2009) 17-21.24. N. Richter, R. Simon, W. Kroutil, J. Ward, H. Hailes, Synthesis of pharmaceutically relevant 17-α-amino steroids using an ω-transaminase, Chem. Commun., 50 (2014) 6098-6100.25. T. Curran, G. Flynn, D. Rudisill, P. Weintraub, A novel route to a 4-amino steroid: MDL 19687, Tetrahedron Lett., 36 (1995) 4761-4764.26. A. Averin, E. Ranyuk, N. Lukashev, S. Golub, A. Buryak, I. Beletskaya, Palladium-catalyzed amination in the synthesis of macrocycles comprising cholane, polyamine and pyridine units, Tetrahedron Lett., 49 (2008) 1188-1191.27. L. Figueroa, F. Díaz, M. Rosas, E. García, E. Pool, A. Camacho, M. López, R. García, A facile synthesis and theoretical analysis of a steroid-cyclophano, Lett. Org. Chem., 12 (2015) 614-621.28. R.S. Lankalapalli, J.T. Eckelkamp, D. Sircar, D.A. Ford, P.V. Subbaiah, R. Bittman, Synthesis and antioxidant properties of an unnatural plasmalogen analogue bearing a trans O-vinyl ether linkage, Org. Lett., 11 (2009) 2784-2787.29. E. Buck, Z.J. Song, D. Tschaen, P.G. Dormer, R.P. Volante, P.J. Reider, Ullmann diaryl ether synthesis: Rate acceleration by 2, 2, 6, 6-tetramethylheptane-3, 5-dione, Org. Lett., 4 (2002) 1623-1626.30. T.D. Quach, R.A. Batey, Copper (II)-catalyzed ether synthesis from aliphatic alcohols and potassium organotrifluoroborate salts, Org. Lett., 5 (2003) 1381-1384.31. K.L. Zheng, M.Q. You, W.M. Shu, Y.D. Wu, A.X. Wu, Acid-Mediated Intermolecular [3+ 2] Cycloaddition toward Pyrrolo [2, 1-a] isoquinolines: Total Synthesis of the Lamellarin Core and Lamellarin G Trimethyl Ether, Org. Lett., 19 (2017) 2262-2265.32. L. Figueroa, F. Diaz, M. Rosas, G. Maldonado, E. García, E. Pool, Design and synthesis of some carbamazepine derivatives using several strategies, Lett. Org. Chem., 12 (2015) 394-401.33. V.V. Brei, S.V. Prudius, O.V. Melezhyk, Vapour-phase nitration of benzene over superacid WO3/ZrO2 catalysts, Appl. Catal. A., 239 (2003) 11-16.34. H. Sato, K. Hirose, Vapor-phase nitration of benzene over solid acid catalysts (1): Nitration with nitric oxide (NO2), Appl. Catal. A., 174 (1998) 77-81.35. H. Sato, K. Hirose, K. Nagai, H. Yoshioka, Y. Nagaoka, Vapor phase nitration of benzene over solid acid catalysts: II. Nitration with nitric acid (1); montmorillonite and mixed metal oxide catalysts, Appl. Catal. A., 175 (1998) 201-207.36. J.V. Crivello, Nitrations and oxidations with inorganic nitrate salts in trifluoroacetic anhydride, J. Org. Chem., 46 (1981) 3056-3060.37. G.A. Olah, H.C. Lin, Aromatic substitution. XXXV. Boron trifluoride catalyzed nitration of benzene, alkylbenzenes, and halobenzenes with methyl nitrate in nitromethane solution, J. Am. Chem. Soc., 96 (1974) 2892-2898.38. M.A. Paul, Ortho-para directive effects for aromatic nitration in acetic anhydride, J. Am. Chem. Soc., 80 (1958) 5332-5333.39. T. Matsumoto, N. Tokitoh, R. Okazaki, First oxazagermete: synthesis, structure and thermal cycloreversioninto a germanone, Chem. Commun., 16 (1997) 1553–1554.40. H.L. Corkins, L. Storace, E.R. Osgood, A new route to the 4H-1, 2-oxazete ring system by the stereospecific oxidation of (Z)-3, 3-dimethyl-1, 1-bis (methylthio)-2-butanone oxime, Tetrahedron Lett., 21 (1980) 2025–2028. 41. W. Walter, W. Ruback, 2,2,4‐Trisubstituted 2H‐1, 3‐Oxazetes‐A New Type of Heterocycles‐A Reinvestigation, Liebigs Ann. Chem., 2 (1982) 231–239.42. K.N. Houk, Frontier molecular orbital theory of cycloaddition reactions, Acc. Chem. Res., 8 (1975) 361-369.43. D.H. Ess, K.N. Houk, Theory of 1, 3-dipolar cycloadditions: distortion/interaction and frontier molecular orbital models, J. Am.Chem. Soc., 130 (2008) 10187-10198.44. Y.R. Prasa, P.R. Kumar, D.J. Smiles, P.A. Babub, QSAR studies on chalcone derivatives as antibacterial agents against Bacillus pumilis, Arkivok., 11 (2008) 266-276.45. J.N. Latosińska, J. Kasprzak, Z. Kazimierczuk, Effects of chlorination and deoxiribose substitution on electron density distribution in indazole molecule studied by 35Cl NQR spectroscopy and ab initio calculations, J. Mol. Struc- THEOCHEM., 530 (2000) 217-222.46. L. Figueroa, F. Díaz, E. Garcia, Synthesis of Two Steroids Derivatives and its Relationship with some Physicochemical Parameters, J. Chem., 9 (2012) 27-34.47. N. Obi-Egbedi, I. Obot, M. El-Khaiary, S. Umoren, E. Ebenso, Computational Simulation and Statistical Analysis on the Relationship Between Corrosion Inhibition Efficiency and Molecular Structure of Some Phenanthroline Derivatives on Mild Steel Surface, Int. J. Electrochem. Sci., 6 (2011) 5649-5675.48. D. Seeliger, B.L. de Groot, Ligand docking and binding site analysis with PyMOL and Autodock/Vina, J. Computer-Aided Mol. Des., 24 (2010) 417-422.49. M.L. Verdonk, V. Berdini, M.J. Hartshorn, W.T. Mooij, C.W. Murray, R.D. Taylor, P. Watson, Virtual screening using protein− ligand docking: avoiding artificial enrichment, J. Chem. Inf. Comp. Sci., 44 (2004) 793-806.50. S.Y. Huang, X. Zou, Advances and challenges in protein-ligand dockin, Int. J. Mol. Sci., 11 (2010) 3016-3034.51. M. Shalbafan, G. Rezaei Behbehani, H. Ghasemzadeh, Study of Interaction of Human Serum Albumin with Doxorubicin (Anti-Cancer Drug) by Docking Simulation, Chem. Methodol., 3 (2019)348-353.52. R.K. Bommeraa, R. Merugu, L. Eppakayala, A Facile Synthesis and Docking Studies of N-(3-(4-Chlorophenoxy) benzyl)-2-methyl-7H-pyrrolo [2, 3-d] pyrimidin-4-amine, Chem. Methodol., 3 (2019) 354-361.53. J. Jays, S. Mohan, J. Saravanan, Molecular Docking Studies of Novel Aminopyrimidines as Potent Antifungal Agents, Chem. Methodol., 3 (2019) 442-450.54. S. Chumsri, T. Howes, T. Bao, G. Sabnis, A. Brodie, Aromatase, aromatase inhibitors, and breast cancer, J. Steroid Biochem. Mol. Biol., 125 (2011) 13-22.